Research Report Mining | Yuanta Securities ( Hong Kong ): Prologis Pharmaceuticals Equity Incentive Plan Released, Performance Bottom Will Emerge, Upgraded to "Buy" Rating

NightAirdropper · 2026-03-13T07:45:51+00:00

Yuanta Securities points out that Puro Pharma has launched a 2026 equity incentive plan covering 96 core management personnel and technical backbone staff. The incentive measures aim to align team interests and unlock growth potential. The company is expected to see weakening domestic centralized procurement impact, smooth international business expansion, and recovery in generic drug business, with sufficient growth momentum ahead. The firm assigns a "Buy" rating.

NightAirdropper

2026-03-13 07:45:51

Abstract generation in progress

Gelonghui March 12 | Guotai Securities (Hong Kong) research report states that Prolor Pharmaceuticals announced its 2026 equity incentive plan, targeting 96 core management and technical personnel in the company’s CDMO business, granting 7.597 million stock options (approximately 0.66% of the company’s total share capital). It is believed that launching an equity incentive plan for core management and technical personnel in the CDMO business at this time will better align the interests of the main business team, further stimulate growth potential, and the performance-based assessment requirements also provide a growth guarantee for the company. Regarding the pharmaceutical business, the impact of domestic centralized procurement is expected to gradually weaken, and international expansion is progressing smoothly. The US generic drug business has started shipping in Q4 2025, and subsequent generic drug business is also expected to rebound. The company’s strategic focus on strengthening the CDMO business is showing results, with sufficient growth momentum moving forward. Currently, the valuation is reasonable, and performance is expected to recover, leading to an upgrade to a “Buy” investment rating.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes